With the Covid-19 outbreak having caused significant disruption to healthcare services, including those for hepatitis C, HCV Action organised a webinar to discuss how services have been affected in different areas across the country and explore how hepatitis C services can most effectively be re-established as we emerge from the early phase of the outbreak. This report provides a summary of the remarks from each of the four speakers and the Q&A which followed.
HCV testing in NSP (Needle and Syringe Provision) Community Pharmacies Pilot (Phase 2)
Download
This report from the London Joint Working Group on Substance Use and Hepatitis C (LJWG) shows the findings from a pilot project providing point of care testing for hepatitis C to people who inject drugs accessing needle and syringe programmes based at community pharmacies in London. Of the 66 people who accepted a test, 39% were hepatitis C RNA positive. 78% of those tested also stated they would prefer to receive HCV treatment in their community pharmacy.
